The effect of opioid antagonists on synergism between dexketoprofen and tramadol

Pharmacological Research

Volumn 60, Issue 4, 2009, Pages 291-295

  Zegpi, C ^a   Gonzalez, C ^a   Pinardi, G ^a   Miranda, H F ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Dexketoprofen; Opioid antagonists; Orofacial formalin test; Synergism; Tramadol

Indexed keywords

DEXKETOPROFEN; FORMALDEHYDE; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE ANTAGONIST; TRAMADOL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; FACE PAIN; INFLAMMATION; MALE; MOUSE; MOUTH PAIN; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL;

ANALGESICS; ANIMALS; DRUG SYNERGISM; KETOPROFEN; MALE; MICE; NARCOTIC ANTAGONISTS; PAIN; TRAMADOL;

EID: 69249229792     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.04.005     Document Type: Article

References (35)

1. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 59 (1994) 9-23
2. Burian M., and Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 10 (2005) 139-154
3. Christie M.J., Connor M., Vaughan C.W., Ingram S.L., and Bagley E.E. Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin Exp Pharmacol Physiol 27 (2000) 520-523
4. Warner T.D., and Mitchell J.A. Cyclooxygenases: new forms, new inhibitors and lessons from the clinic. FASEB J 18 (2004) 790-804
5. Hutt A.J., and Tan S.C. Drug chirality and its clinical significance. Drugs 52 Suppl. 5 (1996) 1-12
6. Mauleón D., Artigas R., García M.L., and Carganico G. Preclinical and clinical development of dexketoprofen. Drugs 52 Suppl. 5 (1996) 24-46
7. Grond S., and Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 43 (2004) 879-923
8. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., and Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 260 (1992) 275-285
9. Bamigbade T.A., Davidson C., Langford R.M., and Stamford J.A. Actions of Tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raffe nucleus. Br J Anaesth 79 (1997) 352-356
10. Kehlet H., and Dahl J.B. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 7 (1993) 1048-1056
11. Shug S.A. Combination analgesia in 2005-a rational approach: focus on paracetamol-tramadol. Clin Rheumatol 25 Suppl. 1 (2006) S16-S21
12. Luccarini P., Childeric A., Gaydier A.M., Voisin D., and Dallel R. The rofacial formalin test in the mouse: a behavioral model for studying physiology and modulation of trigeminal nociception. J Pain 7 (2006) 908-914
13. Miranda H.F., Sierralta F., Volosky L., and Pinardi G. Pharmacological profile of nalbuphine antinociception in mice. Analgesia 2 (1996) 193-197
14. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman & Hall/CRC, New York
15. Satyanarayana P.S.V., Jain N.K., Singh A., and Kulkarni S.K. Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 641-649
16. Zelcer S., Kolesnikov Y., Kovalyshyn I., Pasternak D.A., and Pasternak G.W. Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. Brain Res 1040 (2005) 151-156
17. Miranda H.F., Puig M.M., Dursteler C., Prieto J.C., and Pinardi G. Dexketoprofen-induced antinociception in animal models of acute pain: synergy with morphine and paracetamol. Neuropharmacology 52 (2007) 291-296
18. Goldstein A., Aronow L., and Kalman S.M. Principles of drug action (1974), J. Wiley & Sons Inc., USA p. 91
19. Taiwo Y.O., and Levine J.D. Prostaglandins inhibit endogenous control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 8 (1988) 1346-1349
20. Miranda H.F., Sierralta F., and Pinardi G. An isobolographic analysis of the adrenergic modulation of diclofenac antinociception. Anesth Analg 93 (2001) 430-435
21. Pinardi G., Sierralta F., and Miranda H.F. Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems. Inflammation 25 (2001) 233-239
22. Pinardi G., Sierralta F., and Miranda H.F. Adrenergic mechanisms in antinociceptive effects of non steroidal anti-inflammatory drugs in acute thermal nociception in mice. Inflamm Res 51 (2002) 219-222
23. Jain N.K., Kulkarni S.K., and Singh A. Modulation of NSAID-induced antinociception and anti-inflammatory effects by alpha2-adrenoreceptor agonists with gastroprotective effects. Life Sci 70 (2002) 2857-2869
24. Stein C., and Schäfer M. Periferal opioid analgesia: basic and clinical aspects. Semin Anesth 16 (1997) 112-116
25. Stein C., Schäfer, Cabot P.J., Carter L., Zhang Q., Zhou L., et al. Peripheral opioid analgesia. Pain Rev 4 (1997) 173-187
26. Labuz D., Mousa S.A., Schäfer M., Stein C., and Machelska H. Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res 1260 (2007) 30-38
27. Choi S.S., Han K.J., Lee H.K., Han E.J., and Suh H.W. Possible antinociceptive mechanisms of opioid receptor antagonists in the mouse formalin test. Pharmacol Biochem Behav 75 (2003) 447-457
28. Shen K.F., and Crain S.M. Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res 636 (1994) 286-297
29. Crain S.M., and Shen K.F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low dose naltrexone, unmasking potent opioid analgesia. Brain Res 888 (2001) 75-82
30. Powell K.J., Abul-Husn N.S., Jhamandas A., Olmstead M.C., Beninger R.J., and Jhamandas K. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance and reward in rats. J Pharmacol Exp Ther 300 (2002) 588-596
31. Abul-Husn N.S., Sutak M., Milne B., and Jhamandas K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ- and δ-opioid receptor antagonists. Br J Pharmacol 151 (2007) 877-887
32. Trang T., McNaull B., Quirion R., and Jhamandas K. Involvement of spinal lipoxygenase metabolites in hyperalgesia and opioid tolerance. Eur J Pharmacol 491 (2004) 21-30
33. Vaughan C.W. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurons. J Neurosci 18 (1998) 10269-10276
34. 2C-adrenoceptor knock out mice brain. Eur J Pharmacol 582 (2008) 70-77
35. Raffa R.B., and Stone Jr. D.J. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther 325 (2008) 500-506